Table 4.
Randomized controlled trials in non-AGA conditions
| Author, year | Condition | Age, years | Intervention group | Comparison | Duration, weeks | Results, mean difference hair density/cm2 (SD) between baseline and end of the study | Side effects |
|---|---|---|---|---|---|---|---|
| Duvic M, 199670 | Chemotherapy-induced alopecia | 44 (median) | ●2% MS twice daily, N=10 | ●Placebo, N=9 | Until hair regrowth was dense enough to be parted (mean 148.5 days) | NA | Pruritus 60%, hypertrichosis 38.1%, scalp folliculitis 25% |
| Lee et al, 201482 | Eyebrow hypotrichosis | 30.6 (mean) | ●2% MS twice daily, N=39 | ●Placebo, N=39 | 16 | ●2% MS: 5.1 (5.2) ●Placebo: 1.0 (4.7) |
Mild-moderate side effects 12.8% |
| Worapunpong et al, 201783 | Eyebrow hypotrichosis | 30.7 (mean) | ●1% MS twice daily, N=40 | ●Placebo, N=40 | 16 | ●1% MS: 10.5 (15.0) ●Placebo: 8.1 (10.6) |
Mild itching and burning 22.5% |
| Ingprasert et al, 201685 | Beard enhancement | 20–60 (range) | ●3% MS twice daily, N=23 | ●Placebo, N=23 | 16 | ●3% MS: 5.0 (0.7) ●Placebo: 0.4 (0.3) |
NA |
Abbreviations: AGA, androgenetic alopecia; MS, minoxidil solution; MF, minoxidil foam; NA, not applicable.